4.60
0.36 (8.49%)
| Previous Close | 4.24 |
| Open | 4.30 |
| Volume | 1,309,100 |
| Avg. Volume (3M) | 888,611 |
| Market Cap | 569,834,688 |
| Price / Sales | 6.62 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Profit Margin | -197.64% |
| Operating Margin (TTM) | -123.58% |
| Diluted EPS (TTM) | -1.42 |
| Quarterly Revenue Growth (YOY) | 27.60% |
| Current Ratio (MRQ) | 4.46 |
| Operating Cash Flow (TTM) | -136.07 M |
| Levered Free Cash Flow (TTM) | -110.34 M |
| Return on Assets (TTM) | -27.02% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | ADC Therapeutics SA | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.75 |
|
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 21.58% |
| % Held by Institutions | 66.89% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Prosight Management, Lp | 30 Sep 2025 | 7,472,303 |
| Tcg Crossover Management, Llc | 30 Sep 2025 | 1,390,175 |
| Lynx1 Capital Management Lp | 30 Sep 2025 | 1,325,848 |
| Platinum Investment Management Ltd | 30 Sep 2025 | 1,156,721 |
| 52 Weeks Range | ||
| Median | 7.00 (52.17%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 16 Oct 2025 | 7.00 (52.17%) | Buy | 4.13 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Dec 2025 | Announcement | ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial |
| 01 Dec 2025 | Announcement | ADC Therapeutics Makes Grants to New Employees Under Inducement Plan |
| 10 Nov 2025 | Announcement | ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update |
| 03 Nov 2025 | Announcement | ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025 |
| 27 Oct 2025 | Announcement | ADC Therapeutics to Present at November Investor Conferences |
| 13 Oct 2025 | Announcement | ADC Therapeutics Announces $60 Million Private Placement |
| 01 Oct 2025 | Announcement | ADC Therapeutics Makes Grants to New Employees Under Inducement Plan |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |